Bicycle Therapeutics plc American Depositary Shares (BCYC)

Price$4.20

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-51.78%

Price vs S&P 500 (4W)-12.67%

VGM Score41.96

Market Capitalization$297.65M

All Metrics

Book Value / Share (Quarterly)$7.95

P/TBV (Annual)2.17x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)71.22%

Cash Flow / Share (Quarterly)$-3.32

Price vs S&P 500 (YTD)-48.84%

Net Profit Margin (TTM)-344.95%

EPS (TTM)$-3.16

10-Day Avg Trading Volume0.26M

EPS Excl Extra (TTM)$-3.16

Revenue Growth (5Y)47.52%

EPS (Annual)$-3.16

ROI (Annual)-35.85%

Net Profit Margin (5Y Avg)-560.24%

Cash / Share (Quarterly)$8.03

Revenue Growth QoQ (YoY)-91.11%

ROA (Last FY)-30.51%

Revenue Growth TTM (YoY)146.85%

EBITD / Share (TTM)$-3.41

ROE (5Y Avg)-33.37%

Operating Margin (TTM)-381.67%

Cash Flow / Share (Annual)$-3.63

P/B Ratio0.54x

P/B Ratio (Quarterly)0.58x

Net Income / Employee (Annual)$-760,300

EV / Revenue (TTM)-4.11x

Net Interest Coverage (TTM)-26.39x

ROA (TTM)-29.54%

EPS Incl Extra (Annual)$-3.16

Current Ratio (Annual)11.98x

Quick Ratio (Quarterly)12.29x

3-Month Avg Trading Volume0.43M

52-Week Price Return-50.59%

Revenue / Employee (TTM)$220,500

P/S Ratio (Annual)4.10x

Asset Turnover (Annual)0.10x

52-Week High$9.36

Operating Margin (5Y Avg)-599.41%

EPS Excl Extra (Annual)$-3.16

CapEx CAGR (5Y)14.39%

Tangible BV CAGR (5Y)40.61%

26-Week Price Return-43.85%

Quick Ratio (Annual)11.66x

13-Week Price Return-21.50%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.66x

Enterprise Value$-261.01M

Revenue / Share Growth (5Y)14.06%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)14.21%

Revenue / Employee (Annual)$252,000

Pretax Margin (Annual)-301.45%

Cash / Share (Annual)$9.05

3-Month Return Std Dev49.64%

Net Income / Employee (TTM)$-760,500

ROE (Last FY)-35.90%

Net Interest Coverage (Annual)-28.94x

EPS Basic Excl Extra (Annual)$-3.16

Receivables Turnover (TTM)378.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.16

Receivables Turnover (Annual)26.98x

ROI (TTM)-35.68%

P/S Ratio (TTM)4.69x

Pretax Margin (5Y Avg)-566.76%

Revenue / Share (Annual)$1.05

Tangible BV / Share (Annual)$9.06

Price vs S&P 500 (52W)-74.95%

Year-to-Date Return-40.68%

5-Day Price Return-7.28%

EPS Normalized (Annual)$-3.16

ROA (5Y Avg)-23.98%

Net Profit Margin (Annual)-301.66%

Month-to-Date Return-10.45%

Cash Flow / Share (TTM)$-4.79

EBITD / Share (Annual)$-3.47

Operating Margin (Annual)-340.38%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-31.47%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.16

P/TBV (Quarterly)1.41x

P/B Ratio (Annual)0.77x

Pretax Margin (TTM)-342.73%

Book Value / Share (Annual)$8.79

Price vs S&P 500 (13W)-29.75%

Beta1.54x

Revenue / Share (TTM)$0.91

ROE (TTM)-35.74%

52-Week Low$4.08

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.87est. -0.63

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

4.06

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCYCBicycle Therapeutics plc American Depositary Shares	—	C	D	$4.20
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing Bicycles, a novel class of constrained synthetic peptides designed to selectively target cancer cells. Its lead candidate, BT1718, combines a Bicycle targeting moiety with a tumor-killing toxin for oncology indications with high unmet medical needs. The company operates in the United States and United Kingdom.